| Basics |
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.
|
| IPO Date: |
April 1, 2008 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$251.21M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.43%
|
| Avg Daily Range (30 D): |
$0.06 | 3.20%
|
| Avg Daily Range (90 D): |
$0.07 | 3.69%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.87M |
| Avg Daily Volume (30 D): |
3.38M |
| Avg Daily Volume (90 D): |
2.61M |
| Trade Size |
| Avg Trade Size (Sh.): |
510 |
| Avg Trade Size (Sh.) (30 D): |
345 |
| Avg Trade Size (Sh.) (90 D): |
330 |
| Institutional Trades |
| Total Inst.Trades: |
53 |
| Avg Inst. Trade: |
$1.35M |
| Avg Inst. Trade (30 D): |
$1.06M |
| Avg Inst. Trade (90 D): |
$1.84M |
| Avg Inst. Trade Volume: |
.47M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.61M |
| Avg Closing Trade (30 D): |
$1M |
| Avg Closing Trade (90 D): |
$2.87M |
| Avg Closing Volume: |
669.98K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.31
|
$-.07
|
$-.07
|
|
Diluted EPS
|
$-.31
|
$-.07
|
$-.07
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -26.26M
|
$ -6.6M
|
$ -5.81M
|
|
Operating Income / Loss
|
$ -27.18M
|
$ -6.87M
|
$ -6.06M
|
|
Cost of Revenue
|
$ M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 08, 2019:
1:50
|
|
Jan 02, 2018:
1:30
|
|
Nov 14, 2016:
1:20
|
|
|
|
